−1.67USD
−30.01 MUSD
155.00 KUSD
11.85 M
About INmune Bio Inc.
Sector
Industry
CEO
Raymond J. Tesi
Website
Headquarters
Boca Raton
Employees (FY)
17
Founded
2015
ISIN
US45782T1051
FIGI
BBG00LW94L98
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of INMB is 8.37 USD — it has decreased by 4.89% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange INmune Bio Inc. stocks are traded under the ticker INMB.
INmune Bio Inc. is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
INMB stock is 8.31% volatile and has beta coefficient of 0.77. Check out the list of the most volatile stocks — is INmune Bio Inc. there?
One year price forecast for INmune Bio Inc. has a max estimate of 22.00 USD and a min estimate of 16.00 USD.
INMB earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.39 USD resulting in a −22.03% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about INmune Bio Inc. earnings.
INmune Bio Inc. revenue for the last quarter amounts to 43.00 K USD despite the estimated figure of 46.00 K USD. In the next quarter revenue is expected to reach 43.00 K USD.
Yes, you can track INmune Bio Inc. financials in yearly and quarterly reports right on TradingView.
INMB stock has fallen by 23.42% compared to the previous week, the month change is a 24.25% fall, over the last year INmune Bio Inc. has showed a 2.20% increase.
INMB net income for the last quarter is −8.41 M USD, while the quarter before that showed −8.56 M USD of net income which accounts for 1.81% change. Track more INmune Bio Inc. financial stats to get the full picture.
Today INmune Bio Inc. has the market capitalization of 160.19 M, it has decreased by 5.39% over the last week.
No, INMB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, INMB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INmune Bio Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 17.00 employees. See our rating of the largest employees — is INmune Bio Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INmune Bio Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INmune Bio Inc. stock shows the sell signal. See more of INmune Bio Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on INmune Bio Inc. future price: according to them, INMB price has a max estimate of 22.00 USD and a min estimate of 16.00 USD. Read a more detailed INmune Bio Inc. forecast: see what analysts think of INmune Bio Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INmune Bio Inc. EBITDA is −29.74 M USD, and current EBITDA margin is −19.19 K%. See more stats in INmune Bio Inc. financial statements.